Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Cancer Radiother ; 22(8): 763-766, 2018 Dec.
Article in French | MEDLINE | ID: mdl-30337049

ABSTRACT

PURPOSE: We aimed to evaluate therapeutic results of radiotherapy for gastric mucosa-associated lymphoid tissue (MALT) lymphomas. PATIENTS AND METHODS: We reviewed retrospectively the records of 11 patients presenting with gastric MALT lymphoma treated between 1993 and 2014. Patients with low-grade lymphoma in failure after helicobacter eradication had exclusive gastric external radiotherapy. Chemotherapy followed by radiotherapy were indicated in case of high grade lymphoma. Radiotherapy doses range between 30 and 40Gy (2Gy per fraction, five fractions per week). RESULTS: All tumours were IE stage. Seven patients with low-grade lymphoma had radiotherapy. Four patients with high-grade lymphoma received chemotherapy then radiotherapy. Ten patients are in complete remission after treatment achievement. Five and 10 years disease-free survival are 100%. No severe toxicity was seen. CONCLUSION: Eradication of Helicobacter pylori is the mainstay of treatment of gastric MALT. External irradiation is an effective and well-tolerated treatment modality in case of resistance to helicobacter eradication.


Subject(s)
Lymphoma, B-Cell, Marginal Zone/radiotherapy , Stomach Neoplasms/radiotherapy , Adult , Aged , Combined Modality Therapy , Disease-Free Survival , Female , Helicobacter Infections/complications , Helicobacter Infections/drug therapy , Helicobacter pylori , Humans , Lymphoma, B-Cell, Marginal Zone/complications , Lymphoma, B-Cell, Marginal Zone/drug therapy , Male , Middle Aged , Radiotherapy, Adjuvant , Remission Induction , Retrospective Studies , Treatment Outcome
2.
Ann Oncol ; 29(3): 731-736, 2018 03 01.
Article in English | MEDLINE | ID: mdl-29236943

ABSTRACT

Background: Concomitant chemotherapy (CT)-radiotherapy (RT) is a standard of care in locally advanced nasopharyngeal carcinoma (NPC) and a role for induction CT is not established. Methods: Patients with locally advanced NPC, WHO type 2 or 3, were randomized to induction TPF plus concomitant cisplatin-RT or concomitant cisplatin-RT alone. The TPF regimen consisted of three cycles of Docetaxel 75 mg/m2 day 1; cisplatin 75 mg/m2 day 1; 5FU 750 mg/m2/day days 1-5. RT consisted of 70 Gy in 7 weeks plus concomitant cisplatin 40 mg/m2 weekly. Results: A total of 83 patients were included in the study. Demographics and tumour characteristics were well balanced between both arms. Most of the patients (95%) in the TPF arm received three cycles of induction CT. The rate of grade 3-4 toxicity and the compliance (NCI-CTCAE v3) during cisplatin-RT were not different between both arms. With a median follow-up of 43.1 months, the 3-year PFS rate was 73.9% in the TPF arm versus 57.2% in the reference arm [hazard ratio (HR) = 0.44; 95% confidence interval (CI): 0.20-0.97, P = 0.042]. Similarly the 3 years overall survival rate was 86.3% in the TPF arm versus 68.9% in the reference arm (HR = 0.40; 95% CI: 0.15-1.04, P = 0.05). Conclusion: In conclusion, several important aspects can be emphasized: the compliance to induction TPF was good and TPF did not compromise the tolerance of the concomitant RT-cisplatin phase. The improved PFS and overall survival rates needs to be confirmed by further trials.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Induction Chemotherapy/methods , Nasopharyngeal Carcinoma/drug therapy , Nasopharyngeal Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Chemoradiotherapy/methods , Cisplatin/administration & dosage , Cisplatin/adverse effects , Docetaxel/administration & dosage , Docetaxel/adverse effects , Female , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Humans , Induction Chemotherapy/adverse effects , Kaplan-Meier Estimate , Male , Middle Aged , Nasopharyngeal Carcinoma/mortality , Nasopharyngeal Carcinoma/radiotherapy , Nasopharyngeal Neoplasms/mortality , Nasopharyngeal Neoplasms/radiotherapy
3.
Cancer Radiother ; 21(1): 40-44, 2017 Feb.
Article in French | MEDLINE | ID: mdl-28214285

ABSTRACT

PURPOSE: Retrospective analysis of clinical aspects and therapeutic results of nasopharynx cancer local failures. PATIENTS AND METHODS: Forty patients with local failure with or without nodal involvement of nasopharyngeal carcinoma were treated between 1993 and 2013. Reirradiation of nasopharynx was delivered at the dose of 60Gy. Platinum-based chemotherapy was indicated in case of locally advanced disease and/or associated nodal failure. RESULTS: The mean age at diagnosis of primitive tumour was 41.9 years (26-67 years). The mean time of relapse occurrence was 31.7 months (6-104 months). Sixty five percent of failures were confined to the nasopharynx. Nodal failure was seen in 14 cases. Twenty-eight patients had chemotherapy. Twenty-five patients had reirradiation of nasopharynx. Mean follow-up was 98 months (12-191 months). Fourteen patients were still alive and in complete remission. Five-year survival was 40.7%. Xerostomia was the most frequent late toxicity. No haemorrhage was seen. CONCLUSION: Reirradiation is the mainstay treatment of nasopharyngeal local failure. Late toxicity seems to decrease with novel techniques of reirradiation.


Subject(s)
Carcinoma/radiotherapy , Nasopharyngeal Neoplasms/radiotherapy , Radiotherapy, High-Energy , Adult , Aged , Antineoplastic Agents, Alkylating/therapeutic use , Carcinoma/drug therapy , Combined Modality Therapy , Female , Follow-Up Studies , Hearing Loss, Sensorineural/epidemiology , Hearing Loss, Sensorineural/etiology , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis , Male , Middle Aged , Nasopharyngeal Carcinoma , Nasopharyngeal Neoplasms/drug therapy , Neoadjuvant Therapy , Neoplasm Recurrence, Local , Organoplatinum Compounds/therapeutic use , Osteosclerosis/epidemiology , Osteosclerosis/etiology , Radiotherapy, High-Energy/adverse effects , Retrospective Studies , Salvage Therapy , Treatment Outcome , Xerostomia/epidemiology , Xerostomia/etiology
4.
Cancer Radiother ; 19(5): 334-6, 2015 Aug.
Article in French | MEDLINE | ID: mdl-26215365

ABSTRACT

Paratesticular rhabdomyosarcoma is a rare tumor. Multimodality treatment should involve surgery, radiotherapy and chemotherapy, which are indicated according to risk groups. Risk group stratification depends on pretreatment staging and definitive histology. Patients older than 10years or those with suspected lymph nodes on imaging have higher incidence of lymph node involvement. Prognosis is excellent for localized tumors, survival rates exceed 90%. We report a case of embryonal paratesticular rhabdomyosarcoma treated in our institution.


Subject(s)
Rhabdomyosarcoma, Embryonal/pathology , Testicular Neoplasms/pathology , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fatal Outcome , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Male , Retroperitoneal Neoplasms/drug therapy , Retroperitoneal Neoplasms/pathology , Rhabdomyosarcoma, Embryonal/drug therapy , Testicular Neoplasms/drug therapy
5.
Cancer Radiother ; 18(3): 208-10, 2014 Jun.
Article in French | MEDLINE | ID: mdl-24837649

ABSTRACT

Neuroendocrine carcinoma of the head and neck is a rare entity. The parotid gland is the most commonly affected site. A nasopharyngeal site has not been previously described. We report a 35-year-old patient who consulted for tinnitus and nasal obstruction. The assessment found a nasopharyngeal tumour T4N0M0. The patient underwent 6 cycles of chemotherapy based on VP16 and cisplatin, followed by radiotherapy at a dose of 70 Gy to the nasopharynx and 50 Gy to the neck. The evolution was marked by clinical improvement and radiological stability. Six months after the end of treatment, the patient had a local and meningeal relapse. He received palliative care. He died 19 months after the end of treatment.


Subject(s)
Carcinoma, Large Cell/pathology , Carcinoma, Neuroendocrine/pathology , Nasopharyngeal Neoplasms/pathology , Adult , Antineoplastic Agents/therapeutic use , Carcinoma, Large Cell/secondary , Carcinoma, Large Cell/therapy , Carcinoma, Neuroendocrine/secondary , Carcinoma, Neuroendocrine/therapy , Chemotherapy, Adjuvant , Cisplatin/therapeutic use , Etoposide/therapeutic use , Fatal Outcome , Humans , Male , Meningeal Neoplasms/secondary , Nasal Obstruction/etiology , Nasopharyngeal Neoplasms/therapy , Radiotherapy Dosage , Radiotherapy, Adjuvant , Tinnitus/etiology
6.
Cancer Radiother ; 17(8): 768-70, 2013 Dec.
Article in French | MEDLINE | ID: mdl-24269014

ABSTRACT

Metastasis to the central nervous system, either through a hematogenous route or through the cerebrospinal fluid, is extremely rare in nasopharynx cancer. We aim to expose clinical aspects, therapeutic features and prognosis of nasopharyngeal carcinoma with brain metastases. We retrospectively reviewed the medical history of about 420 patients with nasopharyngeal carcinoma treated during 17 years at the university hospital of Sfax (Tunisia). Among them, three patients had brain metastasis. We excluded patients with direct extension to the brain. Tumours of the nasopharynx were locally advanced. The first patient had brain metastases at the initial diagnosis. The two other patients had brain metastases at 10 and 16 months during the follow-up. Ocular signs were the symptoms. Lesions were unique in two patients. Synchronous bone metastases were recorded in the three cases. All patients had whole brain radiation therapy and palliative chemotherapy. All patients had a progression of the disease and died. Brain metastases in nasopharynx cancer represent a rare event. Prognosis is poor, depending on age, surgical excision and synchronous metastases. Survival does not exceed 6 months.


Subject(s)
Brain Neoplasms/secondary , Carcinoma/pathology , Carcinoma/secondary , Nasopharyngeal Neoplasms/pathology , Adult , Antineoplastic Agents/therapeutic use , Bone Neoplasms/secondary , Brain Neoplasms/therapy , Carcinoma/therapy , Chemoradiotherapy , Fatal Outcome , Humans , Male , Middle Aged , Nasopharyngeal Neoplasms/therapy , Neoadjuvant Therapy , Retrospective Studies
7.
Cancer Radiother ; 17(8): 763-7, 2013 Dec.
Article in French | MEDLINE | ID: mdl-24269016

ABSTRACT

PURPOSE: To compare therapeutic results of nasopharyngeal carcinoma between adults and children. PATIENTS AND METHODS: Three hundred and seventy seven patients with nasopharyngeal carcinoma received a radiotherapy between 1993 and 2007. Sixty-nine of them were 20years old or less. Two hundred and sixty eight patients received a chemotherapy (neoadjuvant or concomitant). RESULTS: Overall survival and disease-free survival at 5 years were 67 % and 59.4 % in all patients, respectively. Overall survival rates at 5 years in children and adults were 66 % and 64 %, respectively (P=0.17), disease-free survival rates at 5 years were 66 % and 57 %, respectively (P=0.17). Local failures occurred more frequently in adults than in children (1.4 % versus 14 %). However, metastatic events were frequently seen in children. Late toxicities were important in children, xerostomia was the most common one. CONCLUSION: Despite locally advanced disease in children, therapeutic results were better than in adults but not statistically significant. The use of treatment combination (chemotherapy and radiotherapy) in juvenile nasopharyngeal carcinoma may explain our findings.


Subject(s)
Carcinoma/mortality , Carcinoma/therapy , Nasopharyngeal Neoplasms/mortality , Nasopharyngeal Neoplasms/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Chemotherapy, Adjuvant , Child , Disease-Free Survival , Dose Fractionation, Radiation , Humans , Middle Aged , Neoadjuvant Therapy , Neoplasm Metastasis , Radiotherapy/adverse effects , Retrospective Studies , Xerostomia/etiology , Young Adult
8.
J Gynecol Obstet Biol Reprod (Paris) ; 42(3): 252-61, 2013 May.
Article in French | MEDLINE | ID: mdl-23478043

ABSTRACT

OBJECTIVES: Evaluation of three rounds of mammography screening pilot programme operated between 2004 and 2010 in Sfax by the founders of Dar El Amal association. PATIENTS AND METHODS: A biennial screening was offered to women aged over 45years and residing in five delegations of Sfax. Two radiologists independently interpret the mammograms. RESULTS: Twelve thousand six hundred and fifty-seven mammographies were performed. The rate of participation was 17.35%. Women under 50years had the higher rate of participation (34.7%). Some 17.2%/8% (prevalent/incident round) of participants were recalled for further assessment. The chirurgical biopsy rate was 2.1% in prevalence and 1.34% in incidence. The predictive positive value (PPV) of biopsy was 26.5% and 47.14% in the prevalent and incident rounds, respectively. The cancer detection rate amounted to 5.6‰ in prevalent round and to 6.3‰ in incident round. Twenty-five percent of invasive detected cancers were less or equal to 10mm in size and 65.5% were node-negative. The rate of interval cancer was 0.78‰. The performance of screening in this study was undermined by the relative importance of women younger than 50years. The cost of one test was 26,200TD and the cost of one cancer case screening was 6142TD. CONCLUSION: This study identified the benefits and limitations of this pilot programme to inform policy makers on the importance and feasibility of an organized mammography screening of breast cancer in Tunisia in a context of a generalization.


Subject(s)
Breast Neoplasms/diagnosis , Carcinoma/diagnosis , Early Detection of Cancer/methods , Mammography/statistics & numerical data , Aged , Aged, 80 and over , Biopsy/statistics & numerical data , Breast Neoplasms/epidemiology , Carcinoma/epidemiology , Early Detection of Cancer/statistics & numerical data , Female , Geography , Humans , Incidence , Middle Aged , Patient Participation/statistics & numerical data , Pilot Projects , Prevalence , Tunisia/epidemiology
9.
Pharmacogenomics J ; 10(4): 278-91, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20676067

ABSTRACT

Batch effects are the systematic non-biological differences between batches (groups) of samples in microarray experiments due to various causes such as differences in sample preparation and hybridization protocols. Previous work focused mainly on the development of methods for effective batch effects removal. However, their impact on cross-batch prediction performance, which is one of the most important goals in microarray-based applications, has not been addressed. This paper uses a broad selection of data sets from the Microarray Quality Control Phase II (MAQC-II) effort, generated on three microarray platforms with different causes of batch effects to assess the efficacy of their removal. Two data sets from cross-tissue and cross-platform experiments are also included. Of the 120 cases studied using Support vector machines (SVM) and K nearest neighbors (KNN) as classifiers and Matthews correlation coefficient (MCC) as performance metric, we find that Ratio-G, Ratio-A, EJLR, mean-centering and standardization methods perform better or equivalent to no batch effect removal in 89, 85, 83, 79 and 75% of the cases, respectively, suggesting that the application of these methods is generally advisable and ratio-based methods are preferred.


Subject(s)
Oligonucleotide Array Sequence Analysis/methods , Algorithms , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Databases, Genetic , Female , Gene Expression Profiling/methods , Gene Expression Profiling/standards , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/genetics , Oligonucleotides , Predictive Value of Tests , Quality Control , Reference Standards , Reproducibility of Results , Toxicogenetics/statistics & numerical data
10.
Rev Mal Respir ; 24(8 Pt 2): 6S171-9, 2007 Oct.
Article in French | MEDLINE | ID: mdl-18235411

ABSTRACT

Small cell lung carcinomas are aggressive on account of their high and early risk of dissemination. They represent less than 20% of all lung cancers and only a third of these present with limited stage disease at diagnosis. Currently, treatment is based on synchronous thoracic irradiation and chemotherapy combining platinum salts and etoposide with or without other drugs. Because of the high risk of brain metastases, prophylactic cranial irradiation (PCI) is indicated in patients with a complete response and should be part of the standard management of these patients on the basis of a meta-analysis showing a 5% increase in survival at three years. In limited stage disease 5 year survival rates can reach 25% but the majority of patients will relapse. This progress is the consequence of a better combination of thoracic and cerebral irradiation and polychemotherapy. Even in extensive disease PCI reduces the risk of brain metastases and significantly improves overall survival. Many issues are subject to further clinical research concerning modalities of combination radio-chemotherapy, radiotherapy target volumes, optimum dosage, and the use of drugs in association with irradiation.


Subject(s)
Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/radiotherapy , Lung Neoplasms/drug therapy , Lung Neoplasms/radiotherapy , Combined Modality Therapy , Humans , Radiotherapy Dosage
11.
Cancer Radiother ; 9(8): 587-9, 2005 Dec.
Article in French | MEDLINE | ID: mdl-16236540

ABSTRACT

PURPOSE: The aim of this work is to study the epidemiological, clinical and evolutive characteristics of the erysipela in patients treated for nasopharyngeal carcinoma (NPC). PATIENTS AND METHODS: Between January 1993 and June 2003, 212 patients were treated for NPC in the radiotherapy department of Sfax hospital. Twenty-two patients among them have presented an erysipela. A neoadjuvant chemotherapy was used for 16 patients with N2-N3 disease. Locoregional radiotherapy was delivered for all of patients. RESULTS: The mean age was 35 years (range: 10 and 69), sex-ratio was 1.2. The median delay between the appearance of erysipela and the end of the treatment was 16 months. The main localisation was the face. The main clinical manifestations were fever in 86% of cases and erythema in 77% of cases. Immediate evolution was favorable in all cases after antibiotherapy. Recurrences were observed in 45% in cases. CONCLUSION: Erysipela is a common skin infection readly found in patients with venous insufficiency. In our study we found a significant correlation between the frequency of erysipela and dystrophic complications. The incidence of erysipela in the face and cervical region after radiotherapy is unknown.


Subject(s)
Erysipelas/etiology , Nasopharyngeal Neoplasms/drug therapy , Nasopharyngeal Neoplasms/radiotherapy , Adolescent , Adult , Aged , Child , Face/pathology , Female , Humans , Male , Middle Aged , Neoadjuvant Therapy , Recurrence , Sex Ratio
SELECTION OF CITATIONS
SEARCH DETAIL